Feraheme: Clinical Trials

14 trials of Feraheme, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 terminated, 3 recruiting, 1 withdrawn. 14 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Completed 5, Terminated 5, Recruiting 3, Withdrawn 1
Phase 12Completed 1, Terminated 1

Follow Feraheme: new trials by email Literature Review of Feraheme trials Research Report on Feraheme

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
Ferumoxytol - Epilepsy, Temporal Lobe
Phase 2RecruitingUniversity of Alberta502025-05-012026-05-08
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection - Prematurity, Iron-deficiency
Phase 2RecruitingUniversity of Washington1202022-11-272026-05-26
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging - Glioblastoma
Phase 2TerminatedOHSU Knight Cancer Institute522017-12-202025-09-09
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging - Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Phase 2TerminatedOHSU Knight Cancer Institute22017-11-032022-08-10
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
Ferumoxytol, Magnetic Resonance Imaging - Brain Neoplasm
Phase 2WithdrawnOHSU Knight Cancer Institute2017-10-202021-11-10
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Ferumoxytol, Gadolinium, Magnetic Resonance Imaging - Central Nervous System Neoplasm, Cranial Nerve Disorder
Phase 2RecruitingOHSU Knight Cancer Institute1502017-10-062026-09-14
Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS
Ferumoxytol - AIDS Dementia Complex
Phase 2CompletedBeau Nakamoto302015-02-012017-10-27
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Ferumoxytol, Magnetic Resonance Imaging (MRI) - Prostate Cancer, Bladder Cancer
Phase 2CompletedNational Cancer Institute (NCI)432014-05-152019-09-06
Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery
EPO, Feraheme - Anemia, Cardiovascular Disease
Phase 1 / Phase 2TerminatedUniversity of Texas Southwestern Medical Center52013-04-092020-10-23
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
WB-DW-MR scan, 18-F-FDG PET scan, Ferumoxytol - Cancer
Phase 1 / Phase 2CompletedStanford University1582012-02-222026-10-06
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Feraheme, Magnetic Resonance Imaging (MRI) scan - Bone Cancer, Chondrosarcoma
Phase 2CompletedHeike E Daldrup-Link322011-08-012023-12-27
A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
Ferumoxytol, Iron Sucrose - Iron Deficiency, Anemia
Phase 2CompletedAMAG Pharmaceuticals, Inc.1622010-03-012023-07-25
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging - Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Phase 2TerminatedOHSU Knight Cancer Institute402006-11-162023-09-07
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
Ferumoxytol - Nervous System Diseases, Diagnostic Imaging
Phase 2TerminatedOregon Health and Science University2552004-07-012024-01-30

Conditions studied

Anemia (3)  ·  Anemia, Iron-Deficiency (3)  ·  Brain Neoplasms (3)  ·  Iron Deficiencies (2)  ·  AIDS Dementia Complex (1)  ·  Bone Neoplasms (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Neoplasms (1)  ·  Chondrosarcoma (1)  ·  Cranial Nerve Diseases (1)  ·  Dementia (1)  ·  Epilepsy, Temporal Lobe (1)  ·  Glioblastoma (1)  ·  Kidney Diseases (1)  ·  Kidney Neoplasms (1)

Sponsors

OHSU Knight Cancer Institute (5)  ·  AMAG Pharmaceuticals, Inc. (1)  ·  Beau Nakamoto (1)  ·  Heike E Daldrup-Link (1)  ·  National Cancer Institute (NCI) (1)  ·  Oregon Health and Science University (1)  ·  Stanford University (1)  ·  University of Alberta (1)  ·  University of Texas Southwestern Medical Center (1)  ·  University of Washington (1)

Countries

United States (12)  ·  Canada (2)  ·  Belgium (1)  ·  Germany (1)  ·  India (1)  ·  Poland (1)  ·  United Kingdom (1)

Top investigators

Beau Nakamoto, MD, PhD (1)  ·  Donald Gross, MD (1)  ·  Edward A Neuwelt (1)  ·  Edward A Neuwelt, MD (1)  ·  Edward Neuwelt (1)  ·  Edward Neuwelt, MD (1)  ·  Heike Daldrup-Link (1)  ·  Heike E Daldrup-Link, MD (1)  ·  Ismail B Turkbey, M.D. (1)  ·  Kendell R German, MD (1)  ·  Leslie Muldoon, Ph.D. (1)  ·  Michael F Regner, MD (1)  ·  Neyssa Marina, MD (1)  ·  Philip E. Greilich, MD (1)

Results publications

PMID 24458078, PMID 24559803, PMID 32368961, PMID 34870211, PMID 36999999, PMID 41430711

NIH funding

2009 (1), K08CA237809 (1), R01CA137488 (1), R01CA269231 (1), R01HD107003 (1), R01NS034608 (1), R21NS087951 (1)